In line with our development strategy, we convened an international scientific board in Paris on October 10th, 2016 to advance innovations and knowledge on Glut1DS siagnosis.

This important meeting brought together leading experts in the field, including the esteemed Pr. Darryl De Vivo, a world-renowned pediatric neurologist recognized for his pioneering work in GLUT1 deficiency syndrome (Glut1DS). We are proud to announce that we have developed a diagnostic test specifically for this condition, METAglut1™.

METAglut1™  is our first IVD blood test to aid the early diagnosis of Glut1 Deficiency Syndrom (Glut1DS), also known as De Vivo Disease, a rare neuro metabolic disorder that can significantly impact the lives of affected children.

We believe our diagnostic tool will enable a significant advancement in identifying the condition, leading to profound implcations for patients and their families. And this annual european meeting was the perfect place to share our latest advancements to the Glut1DS community and foster collaborations among the disease’s specialists. 

The board meeting proved to be a fruitful exchange of ideas and insights. Participants expressed their enthusiasm regarding the medical potential of METAFORA’s innovative diagnostic test. Many members of the board predicted that this test could serve as a groundbreaking solution for the rapid and efficient diagnosis of Glut1DS, a condition that has historically posed challenges in early detection.

Beyond the immediate implications for Glut1DS, the discussions also highlighted the potential for METAFORA’s technologies to lead to significant advancements in the fields of oncology and inflammatory diseases. With preliminary results showing promising outcomes, the board members were optimistic about the future breakthroughs that could emerge from METAFORA’s ongoing research and development efforts.

As we continue to push the boundaries of diagnostic capabilities, we are committed to keeping our community informed about the progress made by our dedicated teams. Stay tuned for updates as we strive to make a meaningful impact in the world of diagnostics and improve patient outcomes.